Brian Connolly, MD
Retina Specialist · Rochester, NYNPI 1164401741
Payments from drug & device makers
What this record shows
The money is spread across several categories — ownership interests (56.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by US Retina LLC at 56.6% of the total. Reporting peaked in 2022 at $1,909 and has fallen 67.8% since, to $614 in 2025.
Across 106 payments — averaging $66.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$4K
- Genentech USA, Inc.$665
- Regeneron Healthcare Solutions, Inc.$536
- AbbVie$367
- Astellas Pharma US Inc$239
- Apellis Pharmaceuticals, Inc.$234
- plus $1K from 13 others
Across 169 payments — averaging $9965.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.6M
- Hexal AG$96K
- Roche TCRC, Inc.$3K
What the payments were for
- Food & beverage$3,02943%
- Education$381%
- Ownership interest$3,99557%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $3,995 |
| Genentech USA, Inc. | 18 | $665 |
| Regeneron Healthcare Solutions, Inc. | 14 | $536 |
| AbbVie | 15 | $367 |
| Astellas Pharma US Inc | 8 | $239 |
| Apellis Pharmaceuticals, Inc. | 6 | $234 |
| Eyepoint US, Inc. | 3 | $146 |
| Alimera Sciences, Inc. | 7 | $131 |
| Sandoz | 6 | $130 |
| ANI Pharmaceuticals, Inc. | 5 | $125 |
| Hoffmann-la Roche Limited | 1 | $125 |
| Coherus Oncology, Inc. | 5 | $116 |
| Harrow Eye, LLC | 2 | $64 |
| Novartis | 3 | $53 |
| Genentech, Inc. | 1 | $38 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $35 |
| Spark Therapeutics, Inc. | 2 | $31 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
| Alcon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,062 in reported general payments places this provider in the 70th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 121 | $12,656 |
| Prednisolone Acetate | 246 | $11,299 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $5,338 |
| Difluprednate | 33 | $3,103 |
| Timolol Maleate | 49 | $910 |
| Latanoprost | 123 | $897 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 75 | $836 |
| Tobramycin | 177 | $824 |
| Brimonidine Tartrate | 91 | $752 |
| Ketorolac Tromethamine | 11 | $563 |
| ErythromycinErythromycin Base | 34 | $340 |
| Diclofenac Sodium | 15 | $151 |
| Prednisone | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Rochester
- Matthew WitmerRochester$62K
- Edward HallRochester$38K
- Steven RoseRochester$5K
- Vikas KhetanRochester$3K
- Sana IdreesRochester$2K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.